Stage III Nasopharyngeal Cancer
Current Clinical Trials
Note: Some citations in the text of this section are followed by a level of
evidence. The PDQ editorial boards use a formal ranking system to help the
reader judge the strength of evidence linked to the reported results of a
therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence 1 for more
information.)
Standard treatment options:
- Chemoradiation therapy, as evidenced in INT-0099 2, for example.[1-9]
- High-dose or superfractionated radiation therapy to the primary tumor site
and bilateral neck nodes that are clinically positive.[10-13]
- Neck dissection may be indicated for persistent or recurrent nodes if the
primary tumor site is controlled.[12]
Treatment options under clinical evaluation:
- Neoadjuvant chemotherapy.
Neoadjuvant chemotherapy as given in clinical trials has been used to shrink
tumors, which renders them more definitively treatable with radiation therapy.
Chemotherapy is given prior to the other modalities, hence the designation
neoadjuvant to distinguish it from standard adjuvant therapy, which is given
after or during definitive therapy with radiation or after surgery. Many drug
combinations have been used in neoadjuvant chemotherapy. Two randomized
prospective trials compared combination chemotherapy (cisplatin, epirubicin,
and bleomycin or cisplatin plus fluorouracil [5-FU] infusion) plus radiation therapy to
radiation therapy alone.[1][Level of evidence: 1iiA];[14][Level of evidence: 1iiDii] Although disease-free survival was improved in the chemotherapy group
for both groups, improvement in overall survival was reported only from the
Intergroup trial in which chemotherapy with cisplatin was ever concurrently given.[1] Clinical trials for advanced tumors evaluating the use of chemotherapy before
radiation therapy, concomitant with radiation therapy, or as adjuvant therapy
after radiation therapy should be considered.[15-18]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage III nasopharyngeal cancer 3. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site 4.
References
-
Al-Sarraf M, LeBlanc M, Giri PG, et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 (4): 1310-7, 1998.
[PUBMED Abstract]
-
Teo PM, Chan AT, Lee WY, et al.: Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. Int J Radiat Oncol Biol Phys 43 (2): 261-71, 1999.
[PUBMED Abstract]
-
Chan AT, Teo PM, Ngan RK, et al.: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20 (8): 2038-44, 2002.
[PUBMED Abstract]
-
Huncharek M, Kupelnick B: Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 25 (3): 219-23, 2002.
[PUBMED Abstract]
-
Chua DT, Ma J, Sham JS, et al.: Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 23 (6): 1118-24, 2005.
[PUBMED Abstract]
-
Wee J, Tan EH, Tai BC, et al.: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 (27): 6730-8, 2005.
[PUBMED Abstract]
-
Zhang L, Zhao C, Peng PJ, et al.: Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 23 (33): 8461-8, 2005.
[PUBMED Abstract]
-
Baujat B, Audry H, Bourhis J, et al.: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64 (1): 47-56, 2006.
[PUBMED Abstract]
-
Baujat B, Audry H, Bourhis J, et al.: Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst Rev (4): CD004329, 2006.
[PUBMED Abstract]
-
Mesic JB, Fletcher GH, Goepfert H: Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys 7 (4): 447-53, 1981.
[PUBMED Abstract]
-
Hoppe RT, Goffinet DR, Bagshaw MA: Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy. Cancer 37 (6): 2605-12, 1976.
[PUBMED Abstract]
-
Mendenhall WM, Riggs CE Jr, Cassisi NJ: Treatment of head and neck cancers. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2005, pp 662-732.
-
Johnson CR, Schmidt-Ullrich RK, Wazer DE: Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer 69 (11): 2749-54, 1992.
[PUBMED Abstract]
-
Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 35 (3): 463-9, 1996.
[PUBMED Abstract]
-
Azli N, Armand JP, Rahal M, et al.: Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma nasopharyngeal type. Eur J Cancer 28A (11): 1792-7, 1992.
[PUBMED Abstract]
-
Chan AT, Teo PM, Leung TW, et al.: A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33 (3): 569-77, 1995.
[PUBMED Abstract]
-
Merlano M, Benasso M, Corvò R, et al.: Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88 (9): 583-9, 1996.
[PUBMED Abstract]
-
Jeremic B, Shibamoto Y, Milicic B, et al.: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18 (7): 1458-64, 2000.
[PUBMED Abstract]
|